BCX4430

BCX4430
Systematic (IUPAC) name
(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
Clinical data
Legal status
  • Investigational New Drug
Identifiers
CAS Number 222631-44-9 YesY
PubChem CID 69211190
ChemSpider 8620968
UNII OLF97F86A7 YesY
Chemical data
Formula C11H15N5O3
Molar mass 265.268

BCX4430 (Immucillin-A) is an antiviral drug, an adenosine analog[1] (a type of nucleoside analog).[2] It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection,[1] and development for use in humans is being fast-tracked due to concerns about the lack of treatment options for the ongoing Ebola virus epidemic in West Africa.[3]

See also

References

  1. 1 2 Warren, T. K.; Wells, J.; Panchal, R. G.; Stuthman, K. S.; Garza, N. L.; Van Tongeren, S. A.; Dong, L.; Retterer, C. J.; Eaton, B. P.; Pegoraro, G.; Honnold, S.; Bantia, S.; Kotian, P.; Chen, X.; Taubenheim, B. R.; Welch, L. S.; Minning, D. M.; Babu, Y. S.; Sheridan, W. P.; Bavari, S. (2014). "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430". Nature 508 (7496): 402. doi:10.1038/nature13027. PMID 24590073.
  2. ↑ Kamat SS, Burgos ES, Raushel FM. Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate. Biochemistry. 2013 Oct 22;52(42):7366-8. DOI 10.1021/bi4013287 PMID 24111876
  3. ↑ BioWar Lab Helping To Develop Treatment For Ebola. Paul Rodgers, Forbes Magazine. 8 April 2014


This article is issued from Wikipedia - version of the Saturday, August 29, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.